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http://dx.doi.org/10.1016/j.fjs.2013.Summary Invasive pulmonary aspergillosis (IPA) is a rare, life-threatening infection in liver
transplant recipients. Here, we report a case of primary cutaneous aspergillosis with following
lung involvement in a liver transplant recipient. The survival rate of patients with IPA can be
increased by early diagnosis using high-resolution computed tomography, a combination of two
effective antifungal agents, temporal reduction or cessation of immunosuppressive drugs, and
surgical intervention with video-assisted thoracoscopic surgery.
Copyright ª 2013, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Invasive pulmonary aspergillosis (IPA) is a rare, life-
threatening infection in liver transplant recipients. The
incidence of IPA in liver transplant recipients has been
reported to be 1e8%, with a mortality rate ranging from
83% to 88%.1 Major risk factors associated with IPA include
renal insufficiency, requirement for dialysis, cytomegalo-
virus (CMV) infection, excessive immunosuppression, re-
exploration, extensive use of broad-spectrum antibi-
otics, and organ dysfunction.2 Early diagnosis, fungicidalt of Surgery, Asian Institute
rial Hospital, Number 542,
hua 500, Taiwan.
com.tw (H.-S. Wu).
ight ª 2013, Taiwan Surgical Asso
05.003therapy, surgical debridement, and reduction in immu-
nosuppression have been reported to contribute to suc-
cessful treatment.3
The gold standard for diagnosis involves the use of
invasive procedures, such as bronchoscopy and lung
biopsy,4 to obtain tissue specimens for culture and
histological examination. Laboratory examinations, such
as polymerase chain reaction and detection of gal-
actomannan, have been shown to be beneficial in the
assessment of liver transplant recipients.5,6 Computed
tomography, particularly high-resolution computed to-
mography (HRCT), has been reported to aid in the early
detection of IPA.7 Hereby we present the case of a liver
transplant recipient with primary cutaneous aspergillosis
followed by lung involvement, who was managed suc-
cessfully through detection with the aid of HRCT followed
by the administration of a combination antifungal therapy.ciation. Published by Elsevier Taiwan LLC. All rights reserved.
128 Y.-J. Wu et al.Surgical intervention was employed for removing the
remaining pulmonary lesion.
2. Case report
A 44-year-old man, 50 kg in weight and 152 cm in height,
with a history of alcohol-related liver cirrhosis, underwent
orthotopic liver transplantation. The piggyback technique
was used for vascular anastomosis and duct-to-duct anas-
tomosis without a T-tube was used for biliary reconstruc-
tion. Blood loss was about 3500 mL. He recovered
uneventfully and was discharged 15 days after the opera-
tion. Immunosuppressive medication consisted of a triple
therapy with tacrolimus, myfortic, and prednisolone in the
first 3 months. All the medications were tapered
progressively.
The patient was readmitted with a distended abdomen,
jaundice, and fever on postoperative Day 24. Liver biopsy
revealed focal necrosis and ballooning of hepatocyte with a
positive CMV stain. Treatment began with intravenous
ganciclovir infusion, 5 mg/kg twice daily for 10 days. His
conditions improved and he was discharged. After
discharge, an oral dose of valganciclovir 900 mg once daily
was prescribed as usual for the following months.
Three months after the transplantation, the patient
noticed a nodule on his back. Excisional biopsy showed
cutaneous aspergillosis with necrotizing inflammationFigure 1 Skin lesion consists of marked necrosis and
neutrophil infiltration. Fungus infection with Aspergillus is
considered.(Fig. 1). There was no fever, jaundice, or any other sys-
temic symptom associated with this incidental finding. A
chest radiograph revealed no abnormal finding (Fig. 2A). No
antifungal medication was prescribed in the clinic.
One month after the excisional biopsy of the back
nodule, the patient developed high fever with cough. At
that time, a physical examination showed yellowish skin
discoloration, coarse breathing sounds over both lung
fields, and negative findings for the abdomen. The routine
workup included sputum culture/stain, urine routine/cul-
ture, blood culture, and serum tests for virus including
CMV, EpsteineBarr virus, varicella-zoster virus, hepatitis B
virus, and hepatitis C virus. A chest X-ray revealed multiple
nodules scattered throughout both lungs, with the largest
nodule (measuring 3 cm) being in the upper lobe of the right
lung (RUL; Fig. 2B). HRCT demonstrated multiple patches
infiltrating both lungs, and the largest nodule showed
adjacent ground-glass opacity, which was considered to be
IPA (Fig. 3A). Laboratory tests revealed a normal white cell
count (4500/mL), with a left shift, and elevated values in
the liver function test GOT/GPT (100/88 U/dL) and bilirubin
total/direct (5.8/4/8 mg/dL). C-reactive protein was
17.7 mg/L.
Empiric treatment was initiated with ceftriaxone 1 g
every 12 hours, intravenous caspofungin 50 mg per day, and
oral voriconazole 200 mg every 12 hours. The patient was
on his usual medication, which consisted of an oral dosage
of trimethoprim/sulfamethoxazole, but all the immuno-
suppressive drugs were tapered or discontinued. Three days
later, his spiking fever came down slowly. Another week
later, the fever subsided completely, and the liver func-
tions returned to normal. We then stopped ceftriaxone and
started low-dosage immunosuppressive drugs. After 1
month of medication, HRCT showed that the lung lesions
became mostly invisible, except for the largest nodule in
the RUL, which nevertheless was decreased in size and
better defined (Fig. 3B). Thoracoscopic wedge resection of
the nodular lesion was performed, and the pathologic
report revealed chronic granulomatous inflammation. He
was discharged 12 days after the operation. An oral dose of
voriconazole 200 mg every 12 hours was prescribed to be
continued for another 2 weeks at home. He remained in a
stable condition during follow-up for more than 1 year.3. Discussion
IPA is a rare, life-threatening infection in patients who
undergo solid organ transplantation. Many studies suggest
that the choice of antibiotics should be based on the
reports of positive serum/tissue tests or cultures.4e6 How-
ever, cultures or biopsies are often time consuming and
sometimes lack sensitivity.4 Polymerase chain reaction is
neither standardized nor commercially available.5 False-
positive results in galactomannan detection have been
described in up to 13% of liver transplant patients.6 Herein,
we present a case of primary cutaneous aspergillosis with
secondary lung involvement in a liver transplant recipient.
An early diagnosis was made based on HRCT findings, and
the patient received a combination of antifungal drugs and
video-assisted thoracoscopic surgery (VATS) for the residual
pulmonary nodule.
Figure 2 Chest radiography: (A) there are no abnormal nodules or lesions within the lung field; (B) multiple nodular masses
scattered within the lung field.
Primary cutaneous aspergillosis 129HRCT has been used successfully as a diagnostic tool in
the IPA for bone marrow transplant recipients.7,8 Based on
the typical signs of IPA on HRCT, a 68% reduction in anti-
fungal usage was achieved.7,8 Moreover, patients without
these typical signs on HRCT did not have a diagnosis of IPA.8
HRCT served as an early diagnostic tool in this patient.
Several studies have suggested that a combination
therapy with antifungal agents may improve efficacy over
monotherapy.9,10 Successful outcomes were observed in
55% of neutropenia patients or transplant recipients at the
end of the combination therapy.9,10 There are no specific
guidelines or recommendations for the use of combinationFigure 3 High-resolution computed tomography findings: (A) mu
monary parenchymas (the largest nodule, about 3 cm in size, is loca
and (B) after 1 month of medication, the lung nodules have decretherapy in IPA. For our patient, we prescribed a combina-
tion of antifungal agents and terminated all the immuno-
suppressive drugs to “wake up” the immune defenses
against the fungus temporally. That might have helped
improve his response to the infection.
The pulmonary nodule that remained even after pro-
longed antifungal treatment is the so-called fungal ball or
mycetoma.11 It may cause massive hemoptysis or recur-
rence, and can even prove fatal. These events occur in
50e80% of cases.11 Surgery is the only definitive modality of
treatment.11 It has to be noted that, in recent years, the
development of VATS has reduced postoperative pain andltiple nodular masses of different sizes scattered at both pul-
ted in the right upper lobe with adjacent ground-glass opacity);
ased in size and number.
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morbidity. In our opinion, VATS helped in the successful
completion of treatment for IPA in our patient.
CMV infection can also be a causative factor of IPA.2 This
patient received a graft from a CMV-seropositive donor, and
so his graft was positive for CMV infection about 3 weeks
after transplantation. On his discharge after the CMV
infection, we prescribed a usual dose for the prevention of
possible CMV. Two months later, he developed a cutaneous
fungal lesion. There is no evidence or report to support that
the CMV infection was related to the cutaneous fungal
infection.12
The cutaneous aspergillosis in this patient was classified
as the primary type.12 Surgical excision of the infected
tissue combined with the use of antifungal agents is the
treatment of choice for solid organ transplant recipients
with cutaneous aspergillosis.12,13 Excision of the infected
cutaneous nodule without administering antifungal agents
can be a risk factor for the following lung involvement.
IPA is uncommon but harbors a high mortality in liver
transplant recipients. The survival rate can be elevated by
early diagnosis with HRCT, effective administration of
antifungal agents, temporary reduction or cessation of the
immunosuppressive drugs, and performance of safe VATS
later, if necessary.
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